An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol

SpringerPlus

Table 1 Inhibited tumor growth and body/heart weights after an intrapleural injection of ZOL

Agent (μg/mouse)	Day of agent administration	Tumor weight (average ± SE) (mg)	Body weight (average ± SE) (g)	Heart weight (average ± SE) (mg)
Experiment 1 (assessment of tumor weight: day 28)
PBS	3	491.1 ± 68.4**	ND	ND
ZOL (80 μg)	3	0**	ND	ND
Experiment 2 (assessment of tumor weight: day 28)
PBS	3	384.8 ± 36.8**	15.9 ± 5.1**	99.8 ± 5.2*
ZOL (40 μg)	3	19.8 ± 7.2**	18.9 ± 0.24**	114.5 ± 3.6*
Experiment 3 (assessment of tumor weight: day 35)
PBS	3	197.7 ± 22.9**	18.5 ± 1.0	123.2 ± 5.8
ZOL (40 μg)	3	2.5 ± 1.2**	19.6 ± 0.3	129.5 ± 3.5*
ZOL (15 μg)	3	79.3 ± 13.2**	19.2 ± 0.2	116.6 ± 3.4*
Experiment 4 (assessment of tumor weight: day 28)
PBS	10	377.9 ± 13.3*	16.1 ± 0.4*	ND
ZOL (40 μg)	10	188.6 ± 62.1*	19.2 ± 0.5*	ND

BALB/c nude mice were inoculated with human mesothelioma, MSTO-211H cells (experiment 1, 2 and 4) or EHMES-10 (experiment 3) (1 × 10⁶/mouse), in the intrapleural cavity and were injected with PBS or ZOL (100 μl in volume) on day 3 or 10. Tumor weights were measured on the indicated day and the averages with standard errors are shown (experiment 1; n = 5, experiment 2; n = 6, experiment 3; n = 7, experiment 4; n = 7)
** P < 0.01; * P < 0.05 (experiment 3; difference of tumor weights is statistically significant in any of two groups and that of heart weights is statistically significant only between ZOL 15 μg- and ZOL 40 μg-injected groups)